Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in adolescent atopic dermatitis
NCT05579925Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Oct 2022; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05579925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579925.